NCT05838742 (MARS-17) is a Phase 2 clinical trial of GSK3858279 in Pain, sponsored by GlaxoSmithKline.

Who is sponsoring NCT05838742?

NCT05838742 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT05838742?

Interventions in NCT05838742: GSK3858279, Placebo.

What condition does NCT05838742 study?

NCT05838742 studies Pain, Osteoarthritis, Knee.

Is NCT05838742 still recruiting?

NCT05838742 is currently terminated. Last updated 10 November 2025.

Are results published for NCT05838742?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-11-10 · How we verify

NCT05838742: MARS-17

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain

Terminated Phase 2 Results posted Last updated 10 November 2025

What this trial tests

Phase 2 trial testing GSK3858279 in Pain in 314 participants. Terminated before completion.

Timeline

13 September 2023

Primary endpoint
12 August 2024

3 December 2024

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	314
Start date	13 September 2023
Primary completion	12 August 2024
Estimated completion	3 December 2024
Sites	93 locations across France, South Africa, Japan, United Kingdom, Germany, Mexico, South Korea, Argentina

Drugs / interventions tested

GSK3858279 — full drug profile →
Placebo

Conditions studied

Pain — all drugs for Pain →
Osteoarthritis, Knee — all drugs for Osteoarthritis, Knee →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 40 to 80, any sex, with Pain or Osteoarthritis, Knee. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change From Baseline in Weekly Average of Average Daily Knee Pain Intensity Using Numeric Rating Scale at Week 12 Primary · Baseline (Day -7 to Day -1) and at Week 12

Change from Baseline in knee pain due to Osteoarthritis were reported by weekly average of average daily pain numeric rating scale (NRS) at Week 12. The pain NRS is an 11-point scale (ranging from 0-10) for self-reporting of average daily knee pain where 0 indicates no pain, and 10 indicates the worst possible pain. For each participant, the weekly average of average daily pain score was calculated using the mean value of available daily pain scores falling in the assessment window for each week. A negative change from baseline indicates an improvement in pain. Participants were asked to compl

Group	Value	95% CI
Placebo	-2.13	-2.55 – -1.73
GSK3858279 - 60 mg Weekly	-1.66	-2.24 – -1.10
GSK3858279 - 240 mg Every 2 Weeks	-1.88	-2.46 – -1.31
GSK3858279 - 240 mg Weekly	-1.74	-2.32 – -1.17
GSK3858279 - 360 mg Weekly	-2.03	-2.60 – -1.47

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score At Week 12 Secondary · Baseline (Day 1) and at Week 12

The WOMAC pain subscale have a recall period of 48 hours and includes 5 subscales of pain assessment: 1-walking on flat, 2-going up downstairs, 3-at night while in bed, 4-sitting or lying; 5-standing upright. The total WOMAC pain subscale score ranges from 0-10; where 0 is no pain and 10 is extreme pain. The WOMAC pain subscale score was calculated by taking average of the 5 pain subscales at each visit. Change from baseline was calculated for each visit as the mean WOMAC Pain subscale score minus the mean baseline WOMAC Pain subscale score. A negative change from baseline indicates an improve

Group	Value	95% CI
Placebo	-2.16	-2.59 – -1.74
GSK3858279 - 60 mg Weekly	-2.13	-2.73 – -1.52
GSK3858279 - 240 mg Every 2 Weeks	-2.21	-2.82 – -1.59
GSK3858279 - 240 mg Weekly	-1.95	-2.54 – -1.36
GSK3858279 - 360 mg Weekly	-1.93	-2.52 – -1.36

Change From Baseline in WOMAC Physical Function Subscale Score at Week 12 Secondary · Baseline (Day 1) and at Week 12

The WOMAC function subscale have a recall period of 48 hours and include 17 items of daily function assessments. The total WOMAC physical function subscale score ranges from 0-10 scale; where 0 is no difficulty and 10 is extremely difficult. The WOMAC physical function subscale score was calculated by taking the average of the 17 physical function subscales at each visit. Change from baseline was calculated for each visit as the mean WOMAC function subscale score minus the mean baseline WOMAC function subscale score. Baseline scores for each participant were assigned based on the score measure

Group	Value	95% CI
Placebo	-1.94	-2.36 – -1.53
GSK3858279 - 60 mg Weekly	-1.99	-2.58 – -1.40
GSK3858279 - 240 mg Every 2 Weeks	-1.56	-2.15 – -0.97
GSK3858279 - 240 mg Weekly	-1.65	-2.23 – -1.08
GSK3858279 - 360 mg Weekly	-1.65	-2.22 – -1.11

Change From Baseline in Patient Global Assessment Of Disease (PtGA) at Week 12 Secondary · Baseline (Day 1) and at Week 12

The PtGA is an assessment for disease conditions and intensity of knee osteoarthritis (OA) pain. Participants will respond on a Likert scale ranging from 1-5 based on the question "Considering all the ways in which your knee OA affects you, how do you feel your knee OA is doing today?" and to identify a number from 1 = very good (asymptomatic and no limitation to normal activities) to 5 = "very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher scores indicate worse conditions. Baseline scores for each participant were assigned based on t

Group	Value	95% CI
Placebo	-0.55	-0.74 – -0.38
GSK3858279 - 60 mg Weekly	-0.57	-0.83 – -0.31
GSK3858279 - 240 mg Every 2 Weeks	-0.55	-0.82 – -0.29
GSK3858279 - 240 mg Weekly	-0.55	-0.79 – -0.31
GSK3858279 - 360 mg Weekly	-0.55	-0.79 – -0.31

Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESI) Secondary · Up to 31 weeks

AEs, SAEs, and AESIs were collected. An AE is any untoward medical occurrence in participant, temporally associated with use of study intervention, whether or not considered related to medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, medically important were categorized as SAEs. The AESIs of the study drug included serious and opportunistic infections, tuberculosis (TB) and TB reactivation, serious hypersensitivity reactions and Inj

AEs

Group	Value	95% CI
Placebo	69
GSK3858279 - 60 mg Weekly	29
GSK3858279 - 240 mg Every 2 Weeks	32
GSK3858279 - 240 mg Weekly	32
GSK3858279 - 360 mg Weekly	34

SAEs

Group	Value	95% CI
Placebo	4
GSK3858279 - 60 mg Weekly	3
GSK3858279 - 240 mg Every 2 Weeks	0
GSK3858279 - 240 mg Weekly	1
GSK3858279 - 360 mg Weekly	2

AESIs

Group	Value	95% CI
Placebo	14
GSK3858279 - 60 mg Weekly	3
GSK3858279 - 240 mg Every 2 Weeks	4
GSK3858279 - 240 mg Weekly	2
GSK3858279 - 360 mg Weekly	12

Number of Participants With Greater Than or Equal to (>=) Grade 3 Hematological/Clinical Chemistry Abnormalities According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE) Secondary · Up to 31 weeks

The laboratory measurements included hematology and clinical chemistry. The parameters evaluated were Basophil, Eosinophil, Erythrocyte Mean Corpuscular Hemoglobin, Erythrocyte Mean Corpuscular Volume, Erythrocytes, Hematocrit, Hemoglobin, Lymphocyte, Monocyte, Neutrophils, Platelets and Reticulocytes, Alanine Aminotransferase, Albumin, Alkaline phosphatase, Aspartate Aminotransferase, Bilirubin, Calcium, Creatinine, Direct Bilirubin, Glucose, Potassium, Sodium and Urea. Worst case grade (G) increase from baseline grade was provided for all the laboratory tests that were gradable by National C

AST, Increase to Grade 3

Group	Value	95% CI
Placebo	0
GSK3858279 - 60 mg Weekly	0
GSK3858279 - 240 mg Every 2 Weeks	0
GSK3858279 - 240 mg Weekly	1
GSK3858279 - 360 mg Weekly	0

Creatine Kinase, Worsening to Grade 3

Group	Value	95% CI
Placebo	2
GSK3858279 - 60 mg Weekly	0
GSK3858279 - 240 mg Every 2 Weeks	0
GSK3858279 - 240 mg Weekly	1
GSK3858279 - 360 mg Weekly	0

Creatine Kinase, Worsening to Grade 4

Group	Value	95% CI
Placebo	0
GSK3858279 - 60 mg Weekly	0
GSK3858279 - 240 mg Every 2 Weeks	1
GSK3858279 - 240 mg Weekly	1
GSK3858279 - 360 mg Weekly	0

Gamma Glutamyl Transferase, Worsening to Grade 3

Group	Value	95% CI
Placebo	0
GSK3858279 - 60 mg Weekly	1
GSK3858279 - 240 mg Every 2 Weeks	0
GSK3858279 - 240 mg Weekly	1
GSK3858279 - 360 mg Weekly	1

Gamma Glutamyl Transferase, Worsening to Grade 4

Group	Value	95% CI
Placebo	1
GSK3858279 - 60 mg Weekly	0
GSK3858279 - 240 mg Every 2 Weeks	0
GSK3858279 - 240 mg Weekly	0
GSK3858279 - 360 mg Weekly	0

Lymphocyte count decreased, worsening to Grade 3

Group	Value	95% CI
Placebo	0
GSK3858279 - 60 mg Weekly	1
GSK3858279 - 240 mg Every 2 Weeks	0
GSK3858279 - 240 mg Weekly	0
GSK3858279 - 360 mg Weekly	0

Maximum Concentration (Cmax) of GSK3858279 Secondary · Pre-dose: Day 1, Weeks 1, 2, 4, 8, 10, 11 and 12

Blood samples were collected at the indicated time points for pharmacokinetic (PK) analysis of GSK3858279 . Pharmacokinetic analysis was conducted using a model based analysis using all available data.

Group	Value	95% CI
GSK3858279 - 60 mg Weekly	4603.1	± 48
GSK3858279 - 240 mg Every 2 Weeks	12330.0	± 47
GSK3858279 - 240 mg Weekly	15383.5	± 51
GSK3858279 - 360 mg Weekly	22169.0	± 40

Time to Maximum Plasma Concentration (Tmax) of GSK3858279 Secondary · Pre-dose: Day 1, Weeks 1, 2, 4, 8, 10, 11 and 12

Tmax predicted from the population PK model fitted to GSK3859279 serum concentration time data collected at the indicated time points for PK analysis.

Group	Value	95% CI
GSK3858279 - 60 mg Weekly	1.454	0.78 – 2.04
GSK3858279 - 240 mg Every 2 Weeks	1.751	0.94 – 3.90
GSK3858279 - 240 mg Weekly	1.412	0.88 – 2.26
GSK3858279 - 360 mg Weekly	1.377	0.73 – 2.26

Pre-Dose (Trough) Concentration at the End of the Dosing Interval (Ctau) of GSK3858279 Secondary · Pre-dose: Day 1, Weeks 1, 2, 4, 8, 10, 11 and 12

Ctau predicted from the population PK model fitted to GSK3859279 serum concentration time data collected at the indicated time points for PK analysis.

Group	Value	95% CI
GSK3858279 - 60 mg Weekly	2449.9	± 63
GSK3858279 - 240 mg Every 2 Weeks	3076.6	± 59
GSK3858279 - 240 mg Weekly	7224.0	± 60
GSK3858279 - 360 mg Weekly	11037.5	± 52

Average Concentration Over a Dosing Interval (Cavg) of GSK3858279 Secondary · Pre-dose: Day 1, Weeks 1, 2, 4, 8, 10, 11 and 12

Cavg predicted from the population PK model fitted to GSK3859279 serum concentration time data collected at the indicated time points for PK analysis.

Group	Value	95% CI
GSK3858279 - 60 mg Weekly	3623.3	± 51
GSK3858279 - 240 mg Every 2 Weeks	7176.4	± 48
GSK3858279 - 240 mg Weekly	11760.8	± 53
GSK3858279 - 360 mg Weekly	16997.6	± 42

Area Under the Time-Concentration Curve (AUC) Over the Dosing Interval (0-Tau) (AUC[0-Tau]) of GSK3858279 Secondary · Pre-dose: Day 1, Weeks 1, 2, 4, 8, 10, 11 and 12

AUC(0-tau) predicted from the population PK model fitted to GSK3859279 serum concentration time data collected at the indicated time points for PK analysis.

Group	Value	95% CI
GSK3858279 - 60 mg Weekly	25362.8	± 51
GSK3858279 - 240 mg Every 2 Weeks	100469.4	± 48
GSK3858279 - 240 mg Weekly	82325.8	± 53
GSK3858279 - 360 mg Weekly	118983.5	± 42

Adverse events — posted to ClinicalTrials.gov

Time frame: All-cause mortality, Serious adverse events (SAEs) and non-serious adverse events (Non-SAEs) were collected from the start of the study intervention (Day 1) until follow up of week 31.. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Placebo

Serious: 4/105 (4%)

Deaths: 0/105

GSK3858279 - 60 mg Weekly

Serious: 3/50 (6%)

Deaths: 0/50

GSK3858279 - 240 mg Every 2 Weeks

Serious: 0/51 (0%)

Deaths: 0/51

GSK3858279 - 240 mg Weekly

Serious: 1/51 (2%)

Deaths: 0/51

GSK3858279 - 360 mg Weekly

Serious: 2/53 (4%)

Deaths: 0/53

Serious adverse events (10 terms)

Reaction	System	Placebo	GSK3858279 - 60 mg Weekly	GSK3858279 - 240 mg Every …	GSK3858279 - 240 mg Weekly	GSK3858279 - 360 mg Weekly
Acute coronary syndrome	Cardiac disorders	—	—	—	—	—
Angina pectoris	Cardiac disorders	—	—	—	—	—
Inguinal hernia	Gastrointestinal disorders	—	—	—	—	—
Herpes zoster	Infections and infestations	—	—	—	—	—
Tubo-ovarian abscess	Infections and infestations	—	—	—	—	—
Wound infection	Infections and infestations	—	—	—	—	—
Ankle fracture	Injury, poisoning and procedural complications	—	—	—	—	—
Tibia fracture	Injury, poisoning and procedural complications	—	—	—	—	—
Lipoedema	Metabolism and nutrition disorders	—	—	—	—	—
Transient ischaemic attack	Nervous system disorders	—	—	—	—	—

Other adverse events (13 terms — click to expand)

Reaction	System	Placebo	GSK3858279 - 60 mg Weekly	GSK3858279 - 240 mg Every …	GSK3858279 - 240 mg Weekly	GSK3858279 - 360 mg Weekly
Headache	Nervous system disorders	—	—	—	—	—
Nasopharyngitis	Infections and infestations	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Injection site bruising	General disorders	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—
COVID-19	Infections and infestations	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—
Injection site reaction	General disorders	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—
Fall	Injury, poisoning and procedural complications	—	—	—	—	—

Most-reported serious reactions: Acute coronary syndrome, Angina pectoris, Inguinal hernia, Herpes zoster, Tubo-ovarian abscess, Wound infection, Ankle fracture, Tibia fracture.

Data from ClinicalTrials.gov NCT05838742 adverse events section.

Sponsor's own description

This is dose-finding study of GSK3858279 in participants with moderate to severe knee osteoarthritis pain. The purpose of this study is to investigate and provide the data necessary to select the optimal effective and safe dose(s) of GSK3858279.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Screening of the FDA-approved drug library identifies CCL17 inhibitors that block arthritic pain.
Eivazitork M, Lupancu TJ, Lim K, Huang YK, et al · · 2025 · cited 1× · PMID 40702243 · DOI 10.1038/s41598-025-12191-4

Verify or expand the search:

Other trials of GSK3858279

Trials testing the same drug.

NCT05838755 — A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain · Phase 2 · terminated
NCT05174013 — Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese Pa · Phase 1 · completed
NCT04114656 — Effects of Intravenous GSK3858279 on a Battery of Evoked Pain Tests in Healthy Volunteers · Phase 1 · terminated

Other recruiting trials for Pain

Currently open trials in the same condition.

NCT07533409 — Tactile and Pain Sensory Thresholds and Hand Grip Strength · recruiting
NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older · recruiting
NCT07454993 — The Effect of Music During Colonoscopy · NA · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05838742 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 10 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05838742.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing